Literature DB >> 11454945

Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice.

Y Suginoshita1, Y Tabata, F Moriyasu, Y Ikada, T Chiba.   

Abstract

Frequent and high-dose i.v. injections of interferon-beta (IFN-beta) have been used clinically to treat patients with viral hepatitis despite various side effects. Because side effects are caused by the systemic effects of IFN-beta, the purpose of this study was to target the drug specifically to the liver, thus reducing the adverse events. A chelating residue, diethylenetriaminepentaacetic acid (DTPA), was introduced to pullulan, a water-soluble polysaccharide with a high affinity for the liver. Murine IFN-beta could be coordinately conjugated with the DTPA-pullulan by simple mixing in an aqueous solution containing zinc ion (Zn2+). Intravenous injection of the IFN-beta-DTPA-pullulan conjugate with Zn2+ coordination enhanced liver induction of an antiviral enzyme, 2',5'-oligoadenylate synthetase (2-5AS), to a greater extent than that by free IFN-beta, although the 2-5AS levels in the liver depended on the mixing ratio of the IFN-beta/DTPA residue of DTPA-pullulan/Zn2+. In addition, the duration of the liver 2-5AS induction by the IFN-beta-DTPA-pullulan conjugate with Zn2+ coordination was longer than that by free IFN-beta. The liver targeting of IFN-beta by DTPA-pullulan with Zn2+ coordination may be a promising IFN therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454945

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  High-level expression of a novel liver-targeting fusion interferon with preferred Escherichia coli codon preference and its anti-hepatitis B virus activity in vivo.

Authors:  Xuemei Lu; Jie Wang; Xiaobao Jin; Jiayong Zhu
Journal:  BMC Biotechnol       Date:  2015-06-12       Impact factor: 2.563

2.  IFN-CSP inhibiting hepatitis B virus in HepG2.2.15 cells involves JAK-STAT signal pathway.

Authors:  Xuemei Lu; Jie Wang; Xiaobao Jin; Yanting Huang; Wenting Zeng; Jiayong Zhu
Journal:  Biomed Res Int       Date:  2015-03-16       Impact factor: 3.411

3.  Production of bioactive liver-targeting interferon Mu-IFN-CSP by soluble prokaryotic expression.

Authors:  Along Liu; Shuiqing Gui; Lun Zhang; Zhaoxia Chen; Yanan Tang; Mingzhu Xiao; Jie Wang; Wenbin Liu; Xiaobao Jin; Jiayong Zhu; Xuemei Lu
Journal:  AMB Express       Date:  2017-10-30       Impact factor: 3.298

4.  Construction of a novel liver-targeting fusion interferon by incorporation of a Plasmodium region I-plus peptide.

Authors:  Xuemei Lu; Xiaobao Jin; Yanting Huang; Jie Wang; Juan Shen; Fujiang Chu; Hanfang Mei; Yan Ma; Jiayong Zhu
Journal:  Biomed Res Int       Date:  2014-01-19       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.